Advice on reducing the risk of statin interactions Karen Baxter MSc, MRPharmS and C Rhoda Lee PhD, MRPharmS
|
|
- Dorthy Blankenship
- 5 years ago
- Views:
Transcription
1 Advice on reducing the risk of statin interactions Karen Baxter MSc, MRPharmS and C Rhoda Lee PhD, MRPharmS VM The editors of Stockley s Drug Interactions highlight the potentially serious interactions with statins and the steps that should be taken to avoid them. Figure 1. Myoglobinuria (dark urine) is a symptom of rhabdomyolysis, a major adverse effect of statins associated with higher doses and drug interactions The statins (HMG-CoA reductase inhibitors) are an increasingly widely prescribed group of drugs. Recent recommendations emphasise that more patients are likely to need statin therapy since acceptable limits for cholesterol have been lowered, 1 and that patients are likely to need higher doses of statins to meet the increasingly aggressive management of elevated lipid levels. Therefore, it is likely that higher doses of statins will be prescribed to a wider range of patients. The use of higher doses of statins increases the risks of adverse effects, particularly those occurring as a result of drug interactions. Although the statins are generally well tolerated, they have two major adverse effects: they raise liver enzymes and can cause skeletal muscle disorders, eg myalgia, myopathy and rhabdomyolysis. Rhabdomyolysis can range from asymptomatic elevations in creatine kinase to acute renal failure, and in its severest form may be lifethreatening. As well as elevated creatine kinase levels, signs and symptoms of rhabdomyolysis include muscle pain, weakness and reddish-brown urine (myoglobinuria, see Figure 1). 2 Although one review reported the incidence of mild myopathies with statins alone as about 1-7 per cent, 3 the overall risk of serious myopathy with the statins is quite low and commonly quoted at per cent. However, the incidence seems to rise markedly if other drugs are being taken concurrently. Thus, a literature review of published reports of rhabdomyolysis between 1985 and 2000 found 15 cases with statins alone, but 54 cases when combined with other drugs. 4 Elevated statin levels The exact mechanism by which statins cause muscle disorders is unclear, although it is thought that elevated statin levels play a key role. 4 Any factor that increases these levels, such as the use of higher doses, can therefore raise the risk of precipitating muscle damage. Statin levels can also rise if any drug given at the same time inhibits their metabolism, and this can be a problem both when a new drug is started and Prescriber 5 June
2 when there is a dosage adjustment in a patient previously stable on an interacting combination. Such changes need to be managed carefully. Statin levels can become elevated if the interacting drug inhibits the metabolism of the statin, with the result that it is cleared from the body more slowly and begins to accumulate. Since statins differ in the way that and extent to which they are metabolised, they do not always interact in the same way. Simvastatin is extensively metabolised by the cytochrome P450 isoenzyme CYP3A4, and any drugs that inhibit this enzyme can cause marked rises in blood statin levels. 5 Atorvastatin (Lipitor) is also metabolised by CYP3A4 but has a relatively low affinity for this isoenzyme, 6 which means that CYP3A4 inhibitors cause smaller but still potentially serious elevations in its levels. Fluvastatin (Lescol) is metabolised primarily by CYP2C9 and rosuvastatin (Crestor) by CYP2C9 and CYP2C19 (although the majority is excreted unchanged 7 ), while the cytochrome P450 system does not appear to be involved in the metabolism of pravastatin. 5 P-glycoprotein inhibition The statins are also P-glycoprotein substrates, and may therefore interact due to inhibition of this carrier, which generally results in increased oral bioavailability. 5 Many drugs that are inhibitors of CYP3A4 are also inhibitors of P- glycoprotein and therefore an You can t Any adverse event must be reported to Sankyo Pharma UK Ltd (please see contact details within PI) or via Abbreviated Prescribing Information OLMETEC Film-Coated Tablets (olmesartan medoxomil): Refer to Summary of Product Characteristics before prescribing. Presentation: OLMETEC is supplied as film-coated tablets containing 10mg, 20mg, or 40mg of olmesartan medoxomil. Indications: Treatment of essential hypertension. Dosage: The recommended starting dose is one OLMETEC 10mg tablet daily. OLMETEC tablets should be taken at about the same time each day, with or without food, for example at breakfast time. In patients whose blood pressure is not adequately controlled at this dose, the dose may be increased to 20mg once daily as the optimal dose. If additional blood pressure reduction is required, the OLMETEC dose may be increased to a maximum of 40mg daily or hydrochlorothiazide therapy may be added. Elderly: The maximum dose in elderly patients is 20mg once daily, owing to limited experience of higher dosages in this patient group. Children and adolescents: Safety and efficacy have not been established in children. Renal impairment: The maximum dose in patients with mild to moderate renal impairment is 20mg OLMETEC once daily, owing to limited experience of higher dosages. The use of OLMETEC in patients with severe renal impairment is not recommended. Hepatic impairment: The use of OLMETEC is not recommended since there is only limited experience in this patient group. Contra-indications: Hypersensitivity to any of the ingredients; Second and third trimesters of pregnancy, lactation; biliary obstruction. Warnings and precautions: Pregnancy and lactation: OLMETEC is contraindicated in second and third trimesters of pregnancy and in lactation. Renal impairment: Periodic monitoring of serum potassium and creatinine levels is recommended. Use of OLMETEC is not recommended in patients with severe renal impairment. Renovascular hypertension: There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system (RAAS). A similar effect may be anticipated with angiotensin II receptor antagonists. Intravascular volume depletion: Sodium and/or volume depletion should be corrected before starting treatment with OLMETEC. Aortic or mitral valve stenosis (obstructive hypertrophic cardiomyopathy): As with other vasodilators special caution is recommended. Primary aldosteronism: Not recommended. Hyperkalaemia: Based on experience with other drugs affecting RAAS, hyperkalaemia may occur during treatment in at risk patients. Close monitoring of serum potassium levels in at risk patients is recommended. Hepatic impairment: Use of OLMETEC in patients with hepatic impairment is not recommended. Ethnic differences: As with all other angiotensin II antagonists, the blood pressure lowering effect of OLMETEC may be reduced in black patients. General: The combination of lithium and
3 interaction may occur via both mechanisms. Fibrates The statins may also interact with other drugs that damage muscles, the best-known example being with fibrates. Of the fibrates, gemfibrozil appears to be most commonly implicated, and it has now been shown that it raises the levels of a number of statins. The mechanism for this effect is uncertain, but may involve inhibition of statin glucuronidation. More recently gemfibrozil has also been shown to be an inhibitor of CYP2C8. The most common statin/ fibrate interaction was that between cerivastatin (now withdrawn) and gemfibrozil. This combination was thought to be up to 80 times more likely to cause fatal rhabdomyolysis, and it seems likely that CYP2C8 inhibition was largely responsible for the severity of this interaction. Because rhabdomyolysis with this statin alone appeared to be more common than with other statins, cerivastatin was withdrawn in 2001/2002. Healthcare costs There appears to be very little information about the impact of statin interactions on healthcare costs, but one Canadian study found that patients taking drugs known to interact with statins consumed more than double the healthcare resources of patients taking statins and no interacting drugs. 8 Drug interactions, therefore, greatly control everything......but you have the power to help control BP Olmetec potency puts you in control. Olmetec 20mg delivers more potent BP reduction than losartan 50mg, valsartan 80mg, irbesartan 150mg and candesartan 8mg. 1-3 That s the power you could prescribe. AIIA comparison is at usual maintenance doses 4 Olmesartan medoxomil Power in your hands OLMETEC is not recommended. In patients with severe congestive heart failure or underlying renal disease including renal artery stenosis, treatment with drugs that affect RAAS has been associated with acute hypotension or, rarely, acute renal failure. The possibility of similar effects cannot be excluded with angiotensin II receptor antagonists. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke. Drug interactions: OLMETEC may be administered with or without food. No clinically relevant interactions were observed with pravastatin, hydrochlorothiazide, antacids, warfarin or digoxin. Concomitant use of lithium, NSAIDs, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and drugs that may increase serum potassium levels is not recommended. The blood pressure lowering effect of OLMETEC may be increased by concomitant use of other antihypertensive agents. No clinically relevant interactions between OLMETEC and drugs metabolised by cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 are expected. Effects on ability to drive and use machines: The effect of OLMETEC tablets on the ability to drive has not been specifically studied. Occasionally dizziness or fatigue may occur in patients taking antihypertensive therapy. Side effects: In clinical studies, the overall incidence of treatment-emergent adverse events was comparable to placebo. The only adverse drug reaction that was unequivocally related to treatment was dizziness. Common: Dizziness, bronchitis, cough, pharyngitis, abdominal pain, diarrhoea, dyspepsia, gastroenteritis, nausea, back, joint, skeletal and chest pain, fatigue, influenza-like symptoms, peripheral oedema, haematuria, urinary tract infection, increased creatine phosphokinase, hypertriglyceridaemia, hyperuricaemia, liver enzyme elevations. Uncommon: Vertigo, angina pectoris, rash. Rare: Hyperkalaemia, hypotension. Very Rarely: Hypersensitivity reactions. Postmarketing experience: The following have been reported very rarely (<1/10,000): Thrombocytopenia, abdominal pain, allergic conditions such as angioneurotic oedema, dermatitis allergic, facial oedema, urticaria, acute renal failure, renal insufficiency, asthenia, abnormal renal function tests, abnormal hepatic function tests. Please consult the Summary of Product Characteristics for a full list of side effects. Legal Category: POM. Package quantities, marketing authorisation numbers and basic NHS cost: OLMETEC 10mg (28 tablets), PL 08265/0015, 10.95, OLMETEC 20mg (28 tablets), PL 08265/ , OLMETEC 40mg (28 tablets) PL 08265/ Marketing Authorisation Holder: Sankyo Pharma UK Ltd, Sankyo House, Repton Place, White Lion Road, Amersham, Buckinghamshire, HP7 9LP. OLMETEC is a registered trademark, the property of Sankyo Co., Ltd, Tokyo, Japan. Further information from: Medical Information, Sankyo Pharma UK Ltd, Sankyo House, Repton Place, White Lion Road, Amersham HP7 9LP. Tel: (01494) medinfo@sankyo.co.uk. Date of preparation: January References: 1. Basile JN et al. Journal of Human Hypertension 2006; 20: Oparil S. J Human Hypertens 2001; 3(5): , Brunner HR, Stumpe KO. Clin Drug Invest 2003; 23(7): UK SmPCs accessed Apr 2006 at Date of preparation: April 2006 OLM356
4 Interacting Evidence for an interaction Statin affected/implicated drug atorvastatin fluvastatin pravastatin rosuvastatin simvastatin Amiodarone amiodarone inhibits CYP3A4, and? X X X dose should not there is some evidence of an exceed 20mg daily increased incidence of myopathy unless the clinical when amiodarone is given with high benefit outweighs doses of simvastatin; rhabdomyo- the risks; counsel lysis has been reported in patients on the combination Azithromycin azithromycin did not change X X X X X atorvastatin levels, and would not be expected to interact with other statins Ciclosporin ciclosporin causes marked start at start at start at contraindicated makers advise dose elevations in statin levels (7-fold lowest dose; lowest dose; lowest dose; should not exceed with rosuvastatin), and cases of counsel counsel counsel 10mg daily; be myalgia and/or rhabdomyolysis aware that have been reported with atorva- ciclosporin dosage statin, fluvastatin, pravastatin and adjustments may simvastatin; atorvastatin is also sometimes be reported to increase ciclosporin necessary; counsel levels by 26-54%, whereas simvastatin appears to reduce them by about 30%; fluvastatin, pravastatin and rosuvastatin do not appear to cause significant changes in ciclosporin levels Clarithromycin clarithromycin inhibits CYP3A4 and caution X caution X contraindicated; raises atorvastatin levels, and would advised; advised; withdraw simvatherefore be predicted to raise sim- counsel counsel statin during short vastatin levels; unexpectedly, courses of clarithromycin modestly raises clarithromycin pravastatin levels; rhabdomyolysis has been seen with simvastatin Clopidogrel statins metabolised by the cyto-? X X X? chrome P450 isoenzyme CYP3A4 appear to interfere with the antiplatelet action of clopidogrel; there is insufficient evidence to recommend changes to current practice Colchicine case reports describe myopathy or counsel counsel counsel counsel counsel rhabdomyolysis in patients given colchicine with fluvastatin, pravastatin or simvastatin; this effect seems possible with all statins Table 1. Drug interactions with statins and safety advice Prescriber 5 June
5 Interacting Evidence for an interaction Statin affected/implicated drug atorvastatin fluvastatin pravastatin rosuvastatin simvastatin Danazol severe rhabdomyolysis and myo-? X X X makers advise dose globinuria have been seen when should not exceed simvastatin was given with danazol; 10mg daily; this was possibly due to inhibition counsel of CYP3A4 Diltiazem diltiazem raises simvastatin levels by makers advise X X X makers advise dose inhibition of CYP3A4; rhabdomyo- caution; should not exceed lysis has been seen with diltiazem counsel 40mg daily; and atorvastatin or simvastatin counsel Erythromycin erythromycin inhibits CYP3A4 and caution caution has caution X contraindicated; modestly raises atorvastatin levels, advised; been advised advised; withdraw and would therefore be predicted counsel due to counsel simvastatin during to raise simvastatin levels; problems short courses of unexpectedly, clarithromycin with the other erythromycin modestly raised pravastatin levels macrolides in 1 of 2 studies; erythromycin but no slightly reduces rosuvastatin levels; interaction is unspecified macrolides have been expected implicated in cases of rhabdomyolysis with atorvastatin, pravastatin and simvastatin Fibrates gemfibrozil markedly increases levels undertake with caution caution makers contra- avoid gemfibrozil of pravastatin, rosuvastatin and caution, advised with advised with indicate 40mg where possible; simvastatin, whereas fenofibrate especially all fibrates; all fibrates; dose; rosuva- makers of simvadoes not; because of the increased with counsel counsel statin 5mg statin advise dose risks of muscle toxicity, eg myopathy gemfibrozil; should be used should not exceed or rhabdomyolysis, it is generally counsel to start; 10mg daily, except accepted that use of a statin in counsel with fenofibrate conjunction with a fibrate should where no dose only be undertaken if the benefits restriction is outweigh the risks; the incidence of advised; counsel all statin/fibrate interactions leading to patients myopathy has been put at up to 5%; creatine kinase levels should be measured before initiation Fluconazole fluconazole inhibits the cytochrome caution caution X X contraindicated; P450 isoenzymes CYP2C9 and advised; advised; withdraw CYP3A4 and so causes a modest counsel counsel simvastatin during increase in fluvastatin levels, and short courses of would be predicted to increase fluconazole simvastatin and possibly atorvastatin levels; it has no clinically significant effect on pravastatin or rosuvastatin levels; rhabdomyolysis has been seen when fluconazole is used with atorvastatin and simvastatin Table 1. Drug interactions with statins and safety advice 13 (cont.) 40 Prescriber 5 June
6 Interacting Evidence for an interaction Statin affected/implicated drug atorvastatin fluvastatin pravastatin rosuvastatin simvastatin Fusidic acid 2 cases of rhabdomyolysis have counsel X X X counsel been described in patients given atorvastatin or simvastatin with systemic fusidic acid; fusidic acid was also a possible contributing factor in an interaction attributed to simvastatin and tacrolimus Grapefruit juice grapefruit juice markedly increases small X X X avoid grapefruit the plasma levels of simvastatin, quantities of juice but only modestly affects those of grapefruit atorvastatin; pravastatin seems not juice to interact acceptable Itraconazole itraconazole causes a marked rise in caution X X X contraindicated; the serum levels of atorvastatin and advised; withdraw simvasimvastatin, a nonsignificant change counsel statin during short in pravastatin levels, and no change courses of itraconain fluvastatin or rosuvastatin levels; zole rhabdomyolysis has been seen with simvastatin Ketoconazole there is much less information caution X X X contraindicated; regarding the interactions of advised; withdraw simvaketoconazole and the statins but it counsel statin during short would be expected to interact in the courses of ketosame way as itraconazole; conazole ketoconazole did not change rosuvastatin levels Nicotinic acid cases of rhabdomyolysis have been caution caution caution caution start makers advise dose (Niacin) attributed to the concurrent use of advised; advised; advised; with a 5mg should not exceed nicotinic acid and simvastatin or counsel counsel counsel dose; counsel 10mg daily; counsel pravastatin; nicotinic acid in doses of greater than 1g daily is associated with myopathy Phenytoin in an isolated case, phenytoin it may be it may be X X it may be prudent to reduced the cholesterol-lowering prudent to prudent to check the lipideffect of simvastatin, fluvastatin check the check the lowering effects are and atorvastatin lipid-lowering lipid-lowering adequate effects are effects are adequate; adequate; monitor monitor Protease the levels of atorvastatin and use with X X X contraindicated inhibitors simvastatin appear to be markedly caution and increased by lopinavir/ritonavir, consider a nelfinavir, ritonavir and ritonavir with lower dose saquinavir; 2 cases of rhabdo- (10mg); myolysis have been attributed to counsel Table 1. Drug interactions with statins and safety advice 13 (cont.) Prescriber 5 June
7 Interacting Evidence for an interaction Statin affected/implicated drug atorvastatin fluvastatin pravastatin rosuvastatin simvastatin Protease inhibitors (cont.) ritonavir used with simvastatin; pravastatin does not seem to be significantly affected Rifampicin rifampicin lowers the serum levels of it may be it may be X X it may be prudent to fluvastatin and simvastatin, but an prudent to prudent to check the lipidinteraction has not been widely check the check the lowering effects are reported; it seems likely that lipid-lowering lipid-lowering adequate hepatically metabolised statins will effects are effects are be affected adequate adequate Sildenafil rhabdomyolysis occurred in a patient X X X X consider taking simvastatin and sildenafil; counselling no pharmacokinetic interaction appears to occur between atorvastatin and sildenafil St John s wort St John s wort modestly decreases X X X X it may be prudent to the plasma level of simvastatin, but check the lipidnot pravastatin lowering effects are adequate Tacrolimus an isolated case of rhabdomyolysis X X X X consider occurred following the concurrent counselling use of tacrolimus and simvastatin; the patient was also taking fusidic acid (see above) Telithromycin telithromycin markedly raised simva- contraindica- X X X contraindicated; statin levels, and is predicted to do ted; withdraw withdraw simvathe same with atorvastatin; it is not atorvastatin statin during short expected to interact with fluvastatin during short courses of or pravastatin courses of telithromycin telithromycin Verapamil verapamil inhibits CYP3A4 and? X X X makers advise dose causes marked rises in simvastatin should not exceed levels but serious interactions seem 20mg daily; rare counsel Warfarin case reports suggest that the effects the makers of all the statins advise monitoring, despite little evidence that an of warfarin can be increased by interaction occurs in many cases; fluvastatin shares a metabolic pathway with fluvastatin, rosuvastatin and simva- warfarin and so there is more reason to consider monitoring with this combination statin; studies have not found an interaction; the exception is possibly fluvastatin, where moderate INR increases have been seen more frequently X = not known to be affected/implicated in an interaction? = some uncertainty about any interaction Table 1. Drug interactions with statins and safety advice 13 (cont.) 42 Prescriber 5 June
8 increase the cost of caring for patients taking statins. Recommendations for risk reduction In order to reduce the risks of muscle disorders the CSM (now the Commission on Human Medicines) advises that statins should be used with care in patients who are at increased risk of this adverse effect. 9 Advanced age (said to be over 80 years in the USA and over 70 years in the UK and Australia), 1,10,11 untreated hypothyroidism, alcohol abuse, the perioperative period and impaired renal function (especially related to diabetes) are all independent risk factors for the development of statin-induced myopathy, 1,10,11 and it would be prudent to take a more cautious approach in patients with these co-existent problems. It is also recommended that patients on a statin should be made aware of the risks of myopathy and rhabdomyolysis, and asked to report promptly any unexplained muscle pain, tenderness or weakness, especially if accompanied by malaise, fever or dark urine. 9 In many cases reinforcement of this advice will be sufficient to manage the use of potentially interacting drugs, but in other cases dose adjustments and even temporary withdrawal of the statin may be necessary. Safety advice relating to various interactions is given in Table 1. If symptoms of myopathy occur, creatine kinase should be measured. If this is markedly elevated (some authorities suggest more than five times the upper limit of normal, ULN, 12 and others more than 10 times the ULN 1 ), the statin should be stopped immediately. At lower raised levels (3-10 times the ULN), 1 the patient should be monitored weekly until there is either no longer cause for concern or the statin has to be stopped. 1 Conclusion The incidence of severe adverse interactions with the statins is low, but has the potential to rise as more recent prescribing guidelines are adopted. All statins do not have the same propensity to interact, but in most cases all interactions can be managed by following the simple precautions described here. References 1. Pasternak RC, Smith SC Jr, Bairey- Merz CN, et al; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/ AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106: Allison RC, Bedsole DL. The other medical causes of rhabdomyolysis. Am J Med Sci 2003;326: Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22: Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35: Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42: Roach AE, Tsikouris JP, Haase KK. Rosuvastatin. A new HMG-CoA reductase inhibitor for hypercholesterolemia. Formulary 2002;37: Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 2002;24: CSM/Medicines Control Agency. HMG CoA reductase inhibitors (statins) and myopathy. Current Problems 2002;28: CSM/Medicines and Healthcare products Regulatory Agency. Statins and cytochrome P450 interactions. Current Problems 2004;30: Adverse Drug Reactions Advisory Committee. Risk factors for myopathy and rhabdomyolysis with the statins. Aust Adverse Drug React Bull 2004;23: BNF. No 51, March Baxter K, ed. Stockley s Drug Interactions. London: Pharmaceutical Press. Electronic version (May 2006). Karen Baxter is executive editor and Rhoda Lee is staff editor of Stockley s Drug Interactions Forum If you have any issues you would like to air with your colleagues or comments on articles published in Prescriber, the Editor would be pleased to receive them and, if appropriate, publish them on our Forum page. Please send your comments to: The Editor, Prescriber, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, or to prescriber@wiley.co.uk Prescriber 5 June
There is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.
amciclovir amciclovir + Probenecid Probenecid is predicted to increase the exposure to penciclovir, the active metabolite of famciclovir, possibly resulting in increased adverse effects. Evidence is limited
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology This medicine is used to lower levels of total cholesterol, LDL cholesterol ( bad cholesterol), and fatty substances called triglycerides
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationMICARDIS Composition Pharmacological properties Pharmacokinetics
MICARDIS Boehringer (Tablet) Composition 1 tablet contains 40 or 80 mg [1,1 -biphenyl]-2-carboxylic acid, 4 -[(1,4 dime-thyl- 2 -propyl[2,6-bi-1h-benzimidazole]-1 -yl)methyl] (= telmisartan) Excipients:
More informationNICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant
NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background
More informationROSULIP. Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium).
ROSULIP Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium). Tablets Rosulip 20 mg Each tablet contains 20 mg Rosuvastatin (as calcium). Action Rosuvastatin is a selective and
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Ezetimibe/simvastatin is used to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD). CHD occurs
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationEveness Rosuvastatin. Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt)
Eveness Rosuvastatin Composition Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt) Pharmacological properties Pharmacotherapeutic gruoup: HMG CoA reductase inhibitors Pharmacodynamic
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More informationElements for a Public Summary
Rosuvastatin Stada 5 mg film-coated tablets Rosuvastatin Stada 10 mg film-coated tablets Rosuvastatin Stada 20 mg film-coated tablets Rosuvastatin Stada 40 mg film-coated tablets 25.8.2014, V1.1 PUBLIC
More informationROSUVASTATIN CORE SAFETY PROFILE
ROSUVASTATIN CORE SAFETY PROFILE EU CSP rosuvastatine NL/H/PSUR/00019/005 4.2 Posology and method of administration The recommended start dose is 5 or 10 mg orally once daily in both statin naïve or patients
More informationElements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cardiovascular Events Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationA mong the 20 leading prescription
Safety and Statins: Pharmacologic and Clinical Perspectives Michael B. Bottorff, PharmD A mong the 20 leading prescription drugs in the United States, 3 agents atorvastatin (Lipitor), simvastatin (Zocor),
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationsrmp Atorvastatin Medical Valley
srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationCRESTOR 10 mg, 20 mg, 40 mg ASTRAZENECA
10-14 rosuvastatin calcium Film coated tablets Composition Each tablet contains 5 mg, 10 mg, 20 mg, or 40 mg of rosuvastatin (as calcium salt). Also contains glycerol. Pharmaceutical form Film-coated tablet.
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationATORIS 10, 20, 40 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationCRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets
CRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets COMPOSITION Each film coated tablet contains 10 mg, 20 mg, or 40 mg of rosuvastatin as rosuvastatin calcium. PHARMACEUTICAL FORM Film-coated tablet Round,
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More informationEplerenon Medical Valley + Eplerenon Stada
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Edarbi 20 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg of azilsartan medoxomil (as potassium).
More informationPackage leaflet: Information for the patient. Atorvastatin Krka 40 mg film-coated tablets. Atorvastatin
PACKAGE LEAFLET Package leaflet: Information for the patient Atorvastatin Krka 10 mg film-coated tablets Atorvastatin Krka 20 mg film-coated tablets Atorvastatin Krka 40 mg film-coated tablets Atorvastatin
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr SIMVASTATIN 5 Pr SIMVASTATIN 10 Pr SIMVASTATIN 20 Pr SIMVASTATIN 40 Pr SIMVASTATIN 80 Simvastatin Tablets, USP This leaflet is part III of a three-part Product Monograph
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Simvastatin Accord 10 mg film-coated tablets Simvastatin Accord 20 mg film-coated tablets Simvastatin Accord 40 mg film-coated tablets
More informationCardiovascular Drugs and Therapies HMG CoA a REDUCTASE INHIBITORS (available in Canada)
Trade Name Dosage Forms 10 mg, 20 mg, 40 mg, 80 mg tablets Dosing Range 10-80 mg once daily 2 Dosing Based on Desired LDL Reduction 1,2,3 HMG CoA a REDUCTASE INHIBITORS (available in Canada) LIPITOR, generics
More informationazilsartan medoxomil
azilsartan medoxomil edarbi 40mg Tablet 80mg Tablet ANTIHYPERTENSIVE Angiotensin II Receptor Antagonist FORMULATION: Each tablet contains 40mg Azilsartan medoxomil (as potassium) Each tablet contains 80mg
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationPACKAGE INSERT TEMPLATE FOR ATORVASTATIN TABLET. Brand or Product Name [Product name] Tablet 80mg
PACKAGE INSERT TEMPLATE FOR ATORVASTATIN TABLET Brand or Product Name [Product name] Tablet 10mg [Product name] Tablet 20mg [Product name] Tablet 40mg [Product name] Tablet 80mg Name and Strength of Active
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 24 Scientific conclusions Overall
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationRisk Management Plan
Management Plan Active substance: VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension is generally defined as blood pressure higher than 140/90 mmhg. Hypertension may
More informationAUSTRALIAN PRODUCT INFORMATION. (ezetimibe, rosuvastatin as calcium) Tablets
AUSTRALIAN PRODUCT INFORMATION ROSUZET COMPOSITE PACK (ezetimibe, rosuvastatin as calcium) Tablets 1 NAME OF THE MEDICINE, as calcium 2 QUALITATIVE AND QUANTITATIVE COMPOSITION EZETROL is a white, crystalline
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Sprimeo 150 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg aliskiren
More informationPackage leaflet: Information for the patient. VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride)
Package leaflet: Information for the patient VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationPackage leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium)
PACKAGE LEAFLET Package leaflet: Information for the user Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) Read all of this leaflet carefully before you start taking this medicine because
More informationModule 1.3 Product Information Version: Module Summary of Product Characteristics Replaces :
Irbesartan Apotex Europe B.V. 75 mg, 150 mg, 300 mg film- coated tablets Module 1.3 Product Information Version: 2010-07-01 Module 1.3.1 Summary of Product Characteristics Replaces : 2010-01-20 SUMMARY
More informationZOCOR Merck Sharp & Dhome
ZOCOR Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT Zocor* 5 mg, film-coated tablets. Zocor 10 mg, film-coated tablets. Zocor 20 mg, film-coated tablets. Zocor 40 mg, film-coated tablets. Zocor
More informationP A C K A G E L E A F L E T INFORMATION FOR THE USER. Simvastatin Genericon 20 mg - film-coated tablets
P A C K A G E L E A F L E T INFORMATION FOR THE USER Simvastatin Genericon 20 mg - film-coated tablets Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationPHARMACEUTICAL INFORMATION AZILSARTAN
AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 7
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prilocard 5mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationLOZAR. Composition Each tablet contains Losartan potassium 50 mg.
LOZAR Composition Each tablet contains Losartan potassium 50 mg. Tablets Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is
More informationCiclosporin for Rheumatology and Dermatology use (Adults)
Shared Care Guideline Ciclosporin for Rheumatology and Dermatology use (Adults) Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Irbesartan BMS 75 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg of irbesartan. Excipient:
More informationPackage leaflet: Information for the user. Simidon, 80 mg, film-coated tablets simvastatin
PACKAGE LEAFLET 1 Package leaflet: Information for the user Simidon, 80 mg, film-coated tablets simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationONE REGIMEN, ALL GENOTYPES, 8 WEEKS
For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rasilez 150 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg aliskiren
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cholib 145 mg/20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 145 mg
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Simvastatin 40 mg Film-coated Tablets Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 40 mg of the active
More informationLovastatin tablets 20 and 40 mg PACKAGE LEAFLET
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Lovastatin Mylan 20 mg Tablets Lovastatin Mylan 40 mg Tablets lovastatin Read all of this leaflet carefully before you start taking this medicine.
More informationCONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Simtan 20 mg Film-coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 film-coated tablet contains simvastatin 20 mg. Each film-coated
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each tablet contains 10mg of simvastatin Also contains 74.5mg of lactose, anhydrous
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Simvastatin 10 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10mg of simvastatin Also contains 74.5mg of
More informationAPROVEL 150 mg/300 mg Sanofi-Aventis
APROVEL 150 mg/300 mg Sanofi-Aventis Composition Aprovel 150 mg tablets: each tablet contains 150 mg irbesartan. Aprovel 300 mg tablets: each tablet contains 300 mg irbesartan. Presentation Tablet: White
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationPravastatin Sodium 10 mg Tablets Version 7 SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Product Summary 1. NAME OF THE MEDICINAL PRODUCT Pravastatin Sodium 10 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains pravastatin sodium
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Simvastatin 10 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10mg of simvastatin Also contains 74.5mg of
More information2. What you need to know before you take Simvastatin 20 mg. Package leaflet: Information for the user: simvastatin
1.3.1. Package leaflet Package leaflet: Information for the user: Film-coated Tablets simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationDaiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Daiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In Tokyo, Japan and Basking Ridge, NJ June 6, 2018 Daiichi
More informationSimvastatin 20 mg, film-coated tablets Simvastatin
Proposed Package leaflet Simvastatin 20 mg, film-coated tablets Simvastatin Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to read it again If
More informationRecommendations Contraindicated with VYTORIN
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VYTORIN safely and effectively. See full prescribing information for VYTORIN. VYTORIN (ezetimibe
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationVI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pulmonary arterial hypertension (a high blood pressure in the blood vessels in the lungs) is a rare disease. Historically, the
More informationThe P&T Committee Lisinopril (Qbrelis )
Situation Background Assessment The P&T Committee Lisinopril (Qbrelis ) Qbrelis, 1 mg/ml lisinopril oral solution, has recently become an FDA- approved formulation. Current practice at UK Chandler Medical
More informationPRODUCT INFORMATION TEVETEN. Eprosartan mesylate has a molecular weight (MW) of and may be represented structurally as:
NAME OF THE MEDICINE Non-proprietary Name Eprosartan mesylate Chemical Structure PRODUCT INFORMATION TEVETEN Eprosartan mesylate has a molecular weight (MW) of 520.6 and may be represented structurally
More informationPrescribing Information
Prescribing Information Pr COLCHICINE Colchicine Tablet, USP Preparations with No Effect on Uric Acid Metabolism Odan Laboratories Ltd. Date of Revision: 325 Stillview Avenue May 4, 2016 Pointe-Claire,
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationOlmesartan is used for treating high blood pressure (hypertension) in adult patients.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Olmesartan is used for treating high blood pressure (hypertension) in adult patients. Essential hypertension 1 Worldwide, it is
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Fluvastatin 20mg Capsules Fluvastatin 40mg Capsules UK/H/977/01-02/DC UK licence nos: PL 00289/0997-8 TEVA UK Limited 1 LAY SUMMARY The Medicines Healthcare
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Atorvastatine STADA 10 mg filmomhulde tabletten Atorvastatine STADA 20 mg filmomhulde tabletten Atorvastatine STADA 40 mg filmomhulde tabletten Atorvastatine STADA
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 18 Scientific conclusions Overall
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Crestor 5mg, 10 mg, 20 mg and 40 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains either 5
More informationData Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.
BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Simvastatin 10 mg film-coated tablets Simvastatin 20 mg film-coated tablets Simvastatin 40 mg film-coated tablets Simvastatin 80 mg film-coated tablets Simvastatin
More informationTelmisartan Pritor Tablets
Telmisartan Pritor Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Telmisartan (Pritor TM ) 40 mg Tablet: Each tablet contains 40 mg Telmisartan. Telmisartan (Pritor TM ) 80 mg Tablet: Each tablet contains
More informationkeyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests
www.bpac.org.nz keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests Why do we monitor patients taking diuretics and what do we monitor? Monitoring a person on
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More information